Skip to main content

Table 3 The descriptive data, clinical parameters comparison between responders and non-responders group

From: Role of Strauss ECG criteria as predictor of response in patients undergoing cardiac resynchronization therapy

 

Non-Responders

Responders

Test value

P- value

Sig.

No. = 16

No. = 50

Age

     

Mean ± SD

62.75 ± 5.05

62.52 ± 6.17

0.135•

0.893

NS

Range

53–69

52–74

   

Gender

     

Male

12 (75.0%)

26 (52.0%)

2.625*

0.105

NS

Female

4 (25.0%)

24 (48.0%)

   

BMI

     

Mean ± SD

31.94 ± 4.82

30.54 ± 4.46

1.069•

0.289

NS

Range

26–43

24–46

   

Diabetes

     

Yes

10 (62.5%)

29 (58.0%)

0.102*

0.750

NS

HTN

     

Yes

9 (56.2%)

34 (68.0%)

0.737*

0.391

NS

CKD

     

eGFR > 60

7 (43.8%)

50 (100%)

32.602*

 < 0.001

HS

eGFR30-60

9 (56.2%)

0 (0.0%)

   

Cardiomyopathy

     

DCM

3 (18.8%)

31 (62.0%)

9.078*

0.003

HS

ICM

13 (81.2%)

19 (38.0%)

   

ACEI

     

Yes

7 (43.8%)

43 (86.0%)

11.781*

0.001

HS

ARNI

     

Yes

0 (0.0%)

7 (14.0%)

2.506*

0.113

NS

BB

     

Yes

16 (100.0%)

50 (100.0%)

Diuretics

     

Yes

16 (100.0%)

47 (94.0%)

1.006*

0.316

NS

MRAs

     

Yes

4 (25.0%)

40 (80.0%)

16.500*

 < 0.001

HS

SGLT2 inhibitor

     

Yes

2 (12.5%)

6 (12.0%)

0.003*

0.957

NS

QRS duration (msec)

     

Mean ± SD

135.00 ± 5.16

152.80 ± 24.25

− 2.901•

0.005

HS

Range

130–140

130–200

   

Non-Strauss/Strauss

     

Non-Strauss

10 (62.5%)

26 (52.0%)

0.539*

0.463

NS

Strauss

6 (37.5%)

24 (48.0%)

   

Range

5–15

   
  1. Body mass index, chronic kidney disease, dilated cardiomyopathy, hypertension, ischemic cardiomyopathy, standard deviation, angiotensin converting enzyme inhibitor, angiotensin receptor neutrilypsin inhibitor, beta-blockers, body mass index, chronic kidney disease, dilated cardiomyopathy, mineralocorticoids receptor antagonists, standard deviation, number. *: Chi-square test; •: Independent t-test